Replies to post #37159 on Genta, Inc (fka GNTAQ)

[Smilin_B]

hearing GETA/FDA chatter about positive Phase3 results. Evidently their biomarker approach on low-normal LDH has achieved the holy grail p-value of 0.05 that [FDA] is looking for to approve the drug

What will be the new target on GETA if this is validated?

If the Genasense trial is a success, Genta will displace Vanda Pharmaceuticals(VNDA) as the most shocking, long shot of long shots winner in biotech this year.